Dogwood Therapeutics Inc.

Dogwood Therapeutics Inc. is a development-stage biopharmaceutical company focused on advancing medicines for pain and neuropathy. The company’s current pipeline centers on non-opioid therapies, including Halneuron®, a voltage-gated sodium channel modulator being developed for neuropathic pain and other pain conditions, and SP16, a cell-signaling-based program aimed at neuropathy and nerve damage. Dogwood Therapeutics also works on antiviral combination therapies designed for illnesses linked to virus-triggered immune responses, including pain and fatigue-related disorders. Based in Alpharetta, Georgia, Dogwood Therapeutics operates as a single-segment company with an emphasis on clinical development, preclinical research, and targeted treatment approaches for cancer-related pain, neuropathic disorders, and related conditions.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Gregory Duncan

Employees

8

Headquarters

Alpharetta, GA, United States

Website

dwtx.com